Objective AIO-PK0104 investigated two treatment strategies in advanced pancreatic cancer
(PC): a reference sequence of gemcitabine/erlotinib followed by 2nd-line capecitabine was …

Purpose Renal failure is a frequent complication of multiple myeloma (MM) and, if present at
diagnosis, a considerable risk factor for outcome. Treatment with chemotherapy and/or new …

Introduction Bortezomib is a proteasome inhibitor that has shown important clinical efficacy
either as a single agent or in combination in patients with multiple myeloma (MM). In the …

Background The role of pERK, pAKT and p53 as biomarkers in patients with advanced
pancreatic cancer has not yet been defined. Methods Within the phase III study AIO-PK0104 …

This phase 1 dose finding study tested a combination of lenalidomide, bendamustine and
prednisolone (RBP) in 21 patients in five cohorts with advanced multiple relasped/refractory …

To date, only limited toxicity data are available for the combination of erlotinib with either
capecitabine or gemcitabine as front-line therapy for advanced pancreatic cancer. Within a …

Introduction While lenalidomide monotherapy is established for relapsed and/or refractory
multiple myeloma (MM) treatment, combination therapies including lenalidomide are still …

Background. Drug-induced skin toxicity may correlate with treatment efficacy in cancer
patients receiving chemotherapy or biological agents. The correlation of the capecitabine …

Abstract Treatment of elderly patients (pts) with AML requires a sensitive balance between
efficacy and toxicity. In the AML97 study all pts with AML> 60 years (y) were registered and …

Abstract Abstract 2938 Introduction: Renal impairment is one of the most severe
complications of Multiple Myeloma (MM) at diagnosis. These patients are at increased risk …